## 1 Title: DNA sequencing and gene-expression profiling assists in making a tissue

## 2 of origin diagnosis in cancer of unknown primary

3

#### 4 Authors

| 5  | Atara Posner <sup>1</sup> , Owen W.J. Prall <sup>2</sup> , Tharani Sivakumaran <sup>3,4</sup> , Dariush  |  |  |  |  |  |  |
|----|--|--|--|--|--|--|--|
| 6  | Etemadamoghadam <sup>5</sup> , Niko Thio <sup>5</sup> , Andrew Pattison <sup>1</sup> , Shiva Balachander <sup>1</sup> , Krista                                 |  |  |  |  |  |  |
| 7  | Fisher <sup>5</sup> , Samantha Webb <sup>5</sup> , Colin Wood <sup>5</sup> , Anna DeFazio <sup>6,7,8</sup> , Nicholas Wilcken <sup>9</sup> , Bo                |  |  |  |  |  |  |
| 8  | Gao <sup>9</sup> , Christos S Karapetis <sup>10</sup> , Madhu Singh <sup>11</sup> , Ian M Collins <sup>12</sup> , Gary Richardson <sup>13</sup> ,              |  |  |  |  |  |  |
| 9  | Christopher Steer <sup>14</sup> , Mark Warren <sup>15</sup> , Narayan Karanth <sup>16</sup> , Gavin Wright <sup>17</sup> , Scott                               |  |  |  |  |  |  |
| 10 | Williams <sup>18</sup> , Joshy George <sup>19</sup> , Rodney J Hicks <sup>20</sup> , Alex Boussioutas <sup>21</sup> , Anthony J Gill <sup>22</sup> ,           |  |  |  |  |  |  |
| 11 | Benjamin J. Solomon <sup>3</sup> , Huiling Xu <sup>2</sup> , Andrew Fellowes <sup>2</sup> , Stephen B Fox <sup>2,4</sup> , Penelope                            |  |  |  |  |  |  |
| 12 | Schofield <sup>4,23,24</sup> , David Bowtell <sup>4,5</sup> , Linda Mileshkin <sup><math>*3,4</math></sup> and Richard W. Tothill <sup><math>*1,4</math></sup> |  |  |  |  |  |  |

13

14

Department of Clinical Pathology and Centre for Cancer Research, University of
 Melbourne, Melbourne, Australia

17 2. Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia

18 3. Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne,

19 Australia

4. Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne,
 Australia

22 5. Peter MacCallum Cancer Centre, Melbourne, Australia.

- 23 6. The Westmead Institute for Medical Research, Sydney, Australia
- 24 7. Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia
- 25 8. The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council
- 26 NSW. Sydney, Australia.
- 27 9. Department of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead
- 28 Hospital, Sydney, Australia
- 29 10. Department of Medical Oncology, Flinders University and Flinders Medical Centre,
- 30 Adelaide, Australia
- 31 11. Department of Medical Oncology, Barwon Health Cancer Services, Geelong,
- 32 Australia
- 33 12. Department of Medical Oncology, SouthWest HealthCare, Warrnambool and Deakin
- 34 University, Geelong, Australia
- 35 13. Medical Oncology, Cabrini Health, Melbourne, Australia
- 36 14. Border Medical Oncology, Albury Wodonga Regional Cancer Centre, Albury,
- 37 Australia
- 38 15. Medical Oncology, Bendigo Health, Bendigo, Australia
- 39 16. Division of Medicine, Alan Walker Cancer Centre, Darwin, Australia
- 40 17. Department of Cardiothoracic Surgery, St Vincent's Hospital, Melbourne, Australia
- 41 18. Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne,
- 42 Australia
- 43 19. Department of Computational Sciences, The Jackson Laboratory, Connecticut,
  44 United States

- 45 20. The St Vincent's Hospital Department of Medicine, University of Melbourne,
- 46 Melbourne, Australia
- 47 21. Department of Medicine, Royal Melbourne Hospital, University of Melbourne,
- 48 Melbourne, Australia
- 49 22. Cancer Diagnosis and Pathology Group, Kolling Institute of Medical
- 50 Research and Sydney Medical School, University of Sydney, Sydney, Australia
- 51 23. Department of Psychology, and Iverson Health Innovation Research Institute,
- 52 Swinburne University, Melbourne, Australia
- 53 24. Behavioural Sciences Unit, Health Services Research and Implementation
- 54 Sciences, Peter MacCallum Cancer Centre, Melbourne, Australia
- 55
- 56 \* These authors contributed equally to this work
- 57 Corresponding authors:
- 58 Richard Tothill, 305 Grattan St, Melbourne VIC 3000, rtothill@unimelb.edu.au
- 59 Linda Mileshkin, 305 Grattan St, Melbourne VIC 3000, Linda.Mileshkin@petermac.org

60

61 Competing interest statement: The authors declare no competing financial interests

#### 63 Abstract

64 Cancer of unknown primary (CUP) constitutes a group of metastatic cancers in which 65 standardized clinical investigations fail to identify a tissue of origin (TOO). Gene-expression profiling (GEP) has been used to resolve TOO, and DNA sequencing to identify potential 66 67 targeted treatments; however, these methods have not been widely applied together in CUP 68 patients. To assess the diagnostic utility of DNA and RNA tests for TOO classification, we applied GEP classification and/or gene-panel DNA sequencing in 215 CUP patients. Based on a 69 70 retrospective review of pathology reports and clinical data, 77% of the cohort were deemed 71 True-CUPs (T-CUP). Among the remaining cases, a latent primary diagnosis (10%) (LP-CUP) 72 or TOO was highly suspected based on combined clinicopathological data (13%) (histology-73 resolved CUP, HR-CUP). High-medium confidence GEP classifications were made for 80% of 74 LP/HR-CUPs, and these classifications were consistent with a pathologist-assigned diagnosis in 75 94% of cases, while only 56% of T-CUPs had high-medium confidence predictions. The 76 frequency of somatic mutations in cancer genes was similar to 2,785 CUPs from AACR GENIE 77 Project. DNA features, GEP classification, and oncovirus detection assisted making a TOO 78 diagnosis in 37% of T-CUPs. Gene mutations and mutational signatures of diagnostic utility 79 were found in 31% T-CUPs. GEP classification was useful in 13% of cases and viral detection in 80 4%. Among resolved T-CUPs, lung and biliary were the most frequently identified cancer types, 81 while kidney cancer represented another minor subset. Multivariate survival analysis showed 82 that unresolved T-CUPs had poorer overall survival than LP/HR-CUPs (Hazard ratio=1.9, 95% 83 Cl 1.1 – 3.2, p=0.016), while the risk of death was similar in genomically-resolved T-CUPs and LP/HR-CUPs. In conclusion, combining DNA and RNA profiling with clinicopathological data 84 85 supported a putative TOO diagnosis in over a third of T-CUPs. DNA sequencing benefited T-CUP tumors with atypical transcriptional patterns that hindered reliable GEP classification. 86

## 87 Keywords

- 88 cancer of unknown primary; next-generation sequencing; cancer diagnostic; mutation
- 89 profiling; targeted therapy; tissue of origin classification

## 91 Introduction

Cancer of unknown primary (CUP) represents 1-3% of all cancer diagnoses <sup>1</sup>. It has a 92 notoriously poor outcome, and in Australia, despite being the 14<sup>th</sup> most common 93 diagnosis is the 6<sup>th</sup> most common cause of cancer related death <sup>2</sup>. In the absence of a 94 95 known tissue of origin (TOO), most CUP patients have historically been treated with empirical chemotherapy that is non-durable in most cases<sup>3</sup>. Molecularly targeted 96 treatments and immunotherapies may improve the survival outcome for some CUP 97 patients, although drug access can still be challenging without confirming a TOO 98 diagnosis. Furthermore, a CUP diagnosis brings a heavy psychosocial burden, as 99 patients struggle with the absence of a specific diagnosis leading to feelings of high 100 uncertainty<sup>4</sup>. Therefore, a combination of improved diagnostic and treatment options for 101 people with CUP is urgently needed. 102

103

The guidelines for a CUP diagnosis are currently based on standardized gender-104 105 appropriate histopathological and clinical investigations, as described by the European Society of Medical Oncology (ESMO) <sup>5</sup>. Genomic tests, including gene expression 106 107 profiling (GEP) and DNA methylation analysis, have also been described for making a 108 TOO diagnosis, and some of these tests are commercially available. These classifiers have an accuracy of 83 to 94% when tested on known primary and metastatic tumors <sup>6-</sup> 109 <sup>10</sup> and are superior to immunohistochemistry <sup>11,12</sup>. The diagnostic utility of molecular 110 classifiers has been validated when a latent primary can be found (LP-CUP), in which a 111

primary tumor becomes known in time or through alignment with IHC and other clinicopathological information <sup>6,9,11-13</sup>. However, despite the potential diagnostic value of these molecular tests, their clinical utility is questioned. While retrospective and nonrandomized studies applying site-directed therapies based on predicted TOO have shown survival benefits <sup>14,15</sup>, two randomized clinical trials showed no improvements in patient outcomes <sup>16,17</sup>. As such, the level of recommendation for these tests is low under current guidelines <sup>5</sup>.

119

DNA mutational profiling has also been explored in CUP<sup>18-22</sup>. The primary goal of these 120 121 studies has been to identify actionable mutations to direct targeted therapies with clinically actionable mutations identified in 30-85% of CUP cases <sup>18-22</sup>. However, 122 123 mutational profiling also provides insight into the TOO, given that certain mutational 124 processes and the prevalence of cancer driver mutations can be cancer type-dependent <sup>18</sup>. The availability of large amounts of mutation data in public data repositories enables 125 126 the interpretation of mutations and mutational signatures found in CUP tumors by a priori knowledge of the frequency and specificity across known cancer types <sup>23-27</sup>. Not 127 surprisingly, the integration of genomics with histology to resolve CUP diagnosis is 128 129 making its way into clinical practice<sup>28</sup>.

130

131 While GEP or mutation profiling of CUP has been described independently in previous 132 studies, few studies have considered the diagnostic utility of these assays benchmarked 133 against clinicopathological review. Here we describe the application of GEP and

134 targeted DNA sequencing in a CUP series recruited through a national study (Solving 135 Unknown Primary Cancer: SUPER). Starting from a retrospective review of the available clinicopathological data, we firstly classified CUP cases based on a degree of 136 137 certainty of a single site TOO diagnosis. We then assessed the potential additive diagnostic value of GEP and DNA sequencing in these patient groups. We also 138 compared overall survival differences and the frequency of potential targeted treatments 139 in the CUP groups based on whether genomics and/or clinicopathological review had 140 141 assisted in resolving a TOO diagnosis. We used the observations from this study to 142 support the use of genomics data in the diagnostic workup of CUP patients and to further characterize CUP disease characteristics. 143

- 144
- 145 Methods

#### 146 *Patient cohort*

147 CUP patients were recruited to the SUPER study from 11 Australian sites with informed 148 patient consent under an approved protocol of the Peter MacCallum Cancer Centre 149 (PMCC) human research ethics committee (HREC protocol: 13/62).

Eligibility criteria for patient inclusion in the study were: 1. presenting with carcinoma of no confirmed primary site and who had a preliminary diagnostic workup, including, but not limited to; a detailed clinical assessment; a CT scan of the chest, abdomen, and pelvis; pathological review of tumor tissue; and, other gender-appropriate diagnostic tests; 2. were yet to commence treatment, or had commenced treatment no more than six months prior to recruitment; and 3. could read and write in English, and provide

written informed consent. Exclusion criteria included patients under 18 years of age, who had a poor ECOG performance status (ECOG>=3) or uncontrolled medical or psychological conditions that may have prevented completion of study requirements. Patients were identified and referred by their treating clinician at 11 participating hospitals (Supplementary Methods). Histopathology, clinical characteristics, diagnostic investigations, treatment history, and survival data were collected at baseline, six- and twelve-months post recruitment unless deceased or withdrawn earlier.

Latent primary status was recorded by the treating clinician if a primary tumor was detected with both imaging and histopathology during the study. For study purposes, CUP patients were classified by a medical oncologist (TS) into the ESMO defined clinicopathological subsets defined as favorable and unfavorable prognosis groups, as previously described <sup>5</sup>.

168

### 169 CUP clinicopathological review

170 A retrospective review of all histopathology reports and clinical data was performed by a 171 single pathologist (OP) (Supplementary Table 1-2). A histopathology review of slides was undertaken for a subset of cases from the PMCC (n=59), including additional IHC 172 173 staining if necessary and tissue was available (Supplementary Tables 1-2). Further 174 review of the clinical data was done by a medical oncologist (LM) to concur with the 175 pathologist. Cases were assigned a likely diagnosis where possible, or alternatively, 176 designated as a True-CUP (T-CUP) and then subclassified using a modified version of the Memorial Sloan Kettering Cancer Center OncoTree classification system for CUPs 177

<sup>29</sup>. OncoTree classification included the following: undifferentiated malignant neoplasms 178 179 (UDMN), poorly differentiated carcinoma (PDC), adenocarcinoma, not otherwise 180 specified (ADNOS), neuroendocrine tumors, not otherwise specified (NETNOS), 181 neuroendocrine carcinomas, not otherwise specified (NECNOS) and squamous cell carcinomas, not otherwise specified (SCCNOS). ADNOS were further subdivided based 182 183 on cytokeratin 7 (CK7) and cytokeratin 20 (CK20) IHC staining, and in the case of CK7 184 negative and CK20 positive staining, caudal-type homeobox 2 (CDX2) was annotated. 185 All ADNOS CK7-CK20+ tumors in the cohort had positive IHC staining of CDX2. SCCNOS were further subclassified to "SCC p16+" based on p16INK4A (p16) IHC 186 187 staining positivity, as this increases the likelihood of high-risk human papillomavirus 188 (HPV) infection and raises the possibility of oral, uterine, cervical, or anal mucosal 189 origin. The diagnosis for all cases was re-assessed following the NGS findings.

190

### 191 Gene expression profiling

GEP was performed using a previously described microarray-based test (CUPGuide)<sup>18</sup> 192 193 or a custom NanoString nCounter assay (NanoString Technologies Inc., Seattle, WA, USA). A detailed description of nucleic acid extraction, the NanoString assay and TOO 194 195 classifier is described in Supplementary Methods. Briefly, the NanoString panel included 196 probe sets targeting 225 genes that were differentially expressed across 18 tumor 197 classes, endogenous control genes, and viral transcripts encoding capsid proteins for 198 HPV16 L1, HPV18 L1, and Merkel cell polyomavirus (VP2) (Supplementary Table 3). 199 The NanoString classifier was trained on harmonized TCGA RNA-seq data previously

described <sup>10</sup>, representing 8,454 samples consolidated into 18 tumor classes 200 201 (Supplementary Table 4). Tumor classes SCC and Neuroendocrine represented tumors 202 sharing the respective histological features but originating from multiple tissues in 203 training. The RNA-seq/NanoString k-nearest neighbor cross-platform classifier was validated on an independent test set of 188 metastatic tumors profiled by NanoString 204 (see Supplementary Tables 5-6 for further details on the prediction performance and 205 206 overall accuracy/sensitivity/specificity). A probability score was generated for predictions 207 and heuristic thresholds set for classification confidence level (unclassified <0.5, low  $\geq$ 0.5 and  $\leq$  0.7, medium confidence >0.7 and < 0.9, high confidence  $\geq$ 9 probability). 208

209

## 210 Targeted DNA sequencing

Targeted enrichment and DNA sequencing were performed on matched blood and tumor DNA, capturing coding regions and exon/intron splice sites of 386 cancer-related genes (listed in Supplementary Table 7) using previously described methods <sup>30</sup>. Alignment and variant calling were performed using the ensemble variant caller bcbionextgen cancer somatic variant calling pipelines and R tools used for analysis. A detailed description of bioinformatics is described in Supplementary Methods.

217

#### 218 **Reference mutation data and identification of putative diagnostic DNA features**

The AACR Project GENIE mutation data for 77,058 tumors (version 3.7.9) <sup>23</sup> was downloaded from the cBioPortal webpage (<u>https://genie.cbioportal.org/</u>) <sup>26,27</sup>. The frequency of gene-specific mutations was assessed in tumors annotated as cancer of unknown primary or other cancer types. Genes investigated were restricted to those
included in the targeted capture panel in the current study (Supplementary Table 7). For
assessment of cancer gene driver mutations, GENIE cancer classes with less than 50
samples per class with genes of interest were removed from consideration, except for
assessing gene fusions, where cancer classes with less than 10 samples per cancer
class were removed from analysis (Supplementary Table 8).

228 For identifying DNA features of potential diagnostic utility, the frequency of gene-wise 229 driver mutations was calculated in 22 pre-defined cancer classes (Supplementary Table 8). Oncogenes and tumor suppressor genes (TSGs) were annotated using OncoKB<sup>24</sup>. 230 231 For assessing cancer class mutation frequency in the reference data, only truncating 232 mutations in TSGs or hotspot mutations in both oncogenes and TSGs were used (annotated using the web portal http://www.cancerhotspots.org/)<sup>31</sup>. Oncogenic gene-233 fusions were 234 restricted to those involving the genes FGFR2. FGFR3. ERG. FUS, TMPRSS2, ALK, RET, ROS1, NRG1, NTRK1, NTRK2, NTRK3, and EWSR1. 235 236 Copy-number alterations were restricted to a curated set of frequently amplified cancer 237 genes (Supplementary Table 7). Gene alteration frequencies was calculated within individual cancer classes (Supplementary Table 9). A Fisher's exact test was then 238 239 performed using the R package stats to identify genes statistically enriched for DNA 240 alterations in individual cancer classes versus all other cancers. A post hoc adjusted 241 test was performed using the Holm-Bonferroni method. Significance was defined as 242 anything with an adjusted p-value <0.05 and an odds ratio (OR) greater than 1. These

significant cancers type diagnostic DNA alterations are summarized in SupplementaryTables 9-10.

245

#### 246 Survival analysis

Overall survival (OS) was measured from the date of CUP diagnosis (histologically 247 confirmed) to the date of death from any cause. Thirty-five patients had death recorded 248 249 after completion of study follow-up. Patients without a recorded death were censored 250 based on the date of the last follow-up (12 months). Survival analysis was performed using the R package survival (v3.1-12). Kaplan-Meier estimates of OS were presented 251 252 along with log-rank tests for comparison between resolved and true CUP groups. A cox 253 proportional-hazard model was used for multivariable analysis and adjusted for ECOG 254 (0,1,2,3), age (>60 or <60), gender, and ESMO assigned favorable and unfavorable 255 prognosis groups. Kaplan–Meier produced with and forest plots were 256 the survminer package (v0.4.8.999).

257

#### 258 Results

## 259 Study cohort and subclassification of CUPs

A total of 215 patients were recruited to the SUPER study, and a summary of baseline characteristics is shown in Table 1. Eighty-nine percent (191/215) received GEP, 93% (201/215) of patients had DNA sequencing, and 82% (177/215) received both assays (Table 1). A latent primary (LP-CUP) cancer was reported by the treating clinician during clinical follow-up in 10% (22/215) of cases based on histopathology, clinical

presentation, and/or cancer imaging. In another 13% (27/215) of cases, a likely TOO was assigned after a retrospective review of described morphology, clinical picture, and IHC staining; these cases were termed histology resolved CUP (HR-CUP). Notably, among the LP/HR-CUP cases, there was an enrichment of patients with a prior history of cancer (35%, 17/49), eight of whom likely had a recurrence of their previous disease (Supplementary Table 1).

271

Most of the patients (166/215, 77%) were deemed to be True-CUP (T-CUP) and had 272 sufficient IHC workup according to current ESMO guidelines <sup>5</sup>. Additional IHC stains 273 may have been informative in a small subset (7/166, 4%) but could not be done owing 274 275 to tissue availability. The T-CUPs were classified into histomorphological subtypes using 276 a modified version of the Memorial Sloan Kettering Cancer Center OncoTree 277 classification (see Methods) (Supplementary Table 2). The majority of T-CUPs were adenocarcinomas (51%) or poorly differentiated carcinomas (25%) with minor subsets 278 279 of SCCs (13%), undifferentiated neoplasms (7%), and neuroendocrine neoplasms (2%). The most frequently assigned cancer types for LP/HR-CUPs or CUP OncoTree 280 classifications are summarized in Supplementary Table 11. 281

282

283 GEP classification confidence is lower for True-CUPs than known metastatic 284 cancers

285 We used two GEP methods for TOO classification of 191/215 CUP tumors, where 286 sufficient RNA was available. A previously described 18-class microarray-based classifier (CUPGuide) was used in 20 cases <sup>18</sup>, while a novel NanoString classifier was
used in the remaining cases (Supplementary Table 1-2). The NanoString classifier was
validated using an independent cohort of 188 metastatic tumors of known origin
(Supplementary Table 6), achieving an overall prediction accuracy of 82.9%, increasing
to 91.5% considering only high-medium confidence classifications (n=154) (Figure 1A,
Supplementary Table 5.

293

GEP TOO classification was possible for 45 LP/HR-CUPs (Figure 1B), of which 80% 294 (36/45) had a high-medium confidence classification (Figure 1C). Three LP/HR-CUPs 295 were considered to be outside the 18-class GEP TOO differential, including one rare 296 297 ampullary tumor and two uterine tumors. Among high-medium confidence predictions 298 within the GEP diagnostic differential, 94% (31/33) were concordant with their assigned 299 diagnosis (Supplementary Table 1). Common high-medium confidence misclassifications observed among LP/HR-CUPs as well as the 188 known metastatic 300 301 cancers included cholangiocarcinoma (1/1 and 5/11, respectively) and pancreatic 302 adenocarcinomas (3/10 in the known metastatic group), illustrating classification difficulty among the pancreatobiliary group (Figure 1A, B). 303

304

305 GEP TOO classification was performed on 146 T-CUPs. High-medium confidence 306 classifications were made for only 56% (82/146) of T-CUPs (Figure 1C). The most 307 frequent high-medium confidence classifications included SCC (32%), liver (13%), 308 colorectal (12%), breast (10%) and lung (8.5%) (Figure 1D). A reduced proportion of

high-medium confidence classifications for T-CUPs compared to known metastatic
 cancers suggested T-CUPs either have an atypical transcriptional profile or potentially
 are cancer types outside of the GEP classifier differential.

312

313 The mutation profile of the SUPER CUP cohort is consistent with other CUP 314 cohorts

315 DNA panel sequencing was performed for 201/215 CUP tumors and their matching 316 germline controls. We detected mutational features including single nucleotide variants 317 (SNVs), gene-fusions, copy-number amplifications (CNAs), SNV 96 trinucleotide 318 mutational signatures (COSMIC v2)<sup>32</sup>, tumor mutation burden (TMB), and off-target viral 319 DNA sequences (HPV, EBV) (Figure 2). Viral RNA transcripts detected by NanoString 320 also supported viral status for HPV-positive tumors.

321

322 At least one protein-coding mutation was found in 98.5% (198/201) of all CUPs, with a 323 median TMB of 4.4 mutations/Mb (range 0.5-149 mutations/Mb). The most frequently mutated genes were TP53 (55%), LRP1B (20%), PIK3CA (17%), KMT2D (15%), KRAS 324 325 (12%), ARID1A (11%) and SMARCA4 (11%) (Figure 2). The variant allele frequency of these mutations ranged between 16-40.5%, consistent with clonal cancer driver events 326 when tumor purity was considered. Additionally, 8% (n=16) of the cohort had dominant 327 328 Signature 4 (tobacco smoking), 5% (n=11) Signature 7 (ultra-violet light, UV) and 2% (n=4) Signature 6 (microsatellite instability, MSI). HPV16 (DNA and RNA) was detected 329 330 in five cases and EBV (DNA only) in one case.

331

The gene-wise mutation frequency in the CUP cohort was also compared to 2,785 CUPs with panel sequencing in the AACR Project GENIE database (Figure 2). The mutation profile between the study CUP and GENIE CUP cohorts was highly similar with some minor differences, including a higher frequency of *KRAS* mutations (12% vs. 22%) among the GENIE CUPs and higher *LRP1B* (18% vs. 2%) mutations in the SUPER cohort; the latter explained by *LRP1B* not being included in MSK-IMPACT panel <sup>33</sup>.

339

Actionable mutations were also investigated in reference to the CUPISCO trial criteria of actionability described previously <sup>22</sup>. Eighty-six CUP patients (40%) were matched to either a targeted therapy or immunotherapy arm of CUPISCO (Figure 2) (Supplementary Table 12).

344

#### 345 *Mutation profiling and GEP can augment histopathology review*

We next considered the diagnostic value of DNA and RNA features, including GEP classification in combination with the histopathological review. Here we considered driver gene mutations, gene fusions, mutational signatures, oncoviruses, and highmedium confidence GEP classifications only. To identify gene features with significant cancer type associations, we referenced the GENIE database (77,058 tumor samples) involving 22 solid cancer types. The potential diagnostic utility of a gene feature was determined by comparing one cancer type versus all others (Fisher exact test adjusted p-value < 0.05 and odds-ratio (OR) >1) (Supplementary Table 10). A total of 171 genes were significantly enriched in one or more cancer types, and 90 genes were enriched in only one cancer type (Figure 3A, Supplementary Figure 1). Mutational signatures also provided cumulative evidence to support likely TOO, for example, a Signature 7 (UV) associated with skin cancer or a Signature 4 (tobacco) found in cancers of the airways, although potentially not excluding liver cancer <sup>32</sup>.

359

We first assessed LP/HR-CUP cases that had been assigned a single TOO prior to 360 considering the genomics data. Sixty-nine percent of cases (33/49) had one or more 361 features (RNA and/or DNA) consistent with the TOO diagnosis. Both GEP classification 362 363 and mutation profiling was informative in 20/33 cases, DNA features alone in 7/33, GEP 364 alone in 5/33, and viral detection alone in 1/33 cases. The seven cases where GEP was 365 not informative included two where GEP was not possible, four with low confidence 366 classification, and one was a rare cancer part of the classifier differential. High-medium 367 confidence GEP classifications were the most useful diagnostic feature (n=25) followed by gene mutations (n=24), mutational signatures (n=4), copy number amplifications 368 (n=2), gene-fusions (n=1), and oncoviruses (n=1) (Figure 3B, Supplementary Figure 2). 369

370

Examples of LP/HR-CUP diagnoses supported by genomic data included 8/10 (80%) ovarian cases with high-confidence GEP classification as well as a *TP53* mutation, the latter occurring in >96% of high-grade serous ovarian cancers <sup>34</sup>. A dominant mutation Signature 7 (UV)(n=3) and either oncogenic mutations in *NRAS* (melanoma OR=20.7)

or truncating *NF1* mutations (melanoma OR=5.2) was consistent with cutaneous melanoma <sup>35</sup>. High-confidence GEP prediction of gastric cancer combined with *ERBB2* amplification (concordant with positive HER2 IHC staining) (esophagus/stomach OR=3) and a frameshift deletion in *CDH1* (esophagus/stomach OR=3) supported a diagnosis of gastric adenocarcinoma. High-confidence colorectal GEP prediction and *APC* mutations (colorectal OR= 77.5) were present in two cases diagnosed as colorectal adenocarcinomas <sup>36</sup>(Supplementary Figure 2, Supplementary Table 1).

382

A single HR-CUP (1097) had molecular features resulted in a change in classification from colorectal to T-CUP (ADNOS CK7-CK20+CDX2+). No mutations supported a colorectal origin (e.g., *APC*, *RAS/RAF* mutations), and a high-confidence GEP prediction of kidney with mutations in *NF2* and *SMARCA4* was identified. Confirmatory IHC staining (e.g., for PAX8) may have supported a kidney cancer diagnosis, but no tissue was available.

Molecular features supported a likely single TOO diagnosis consistent with 389 clinicopathological features in 37% (61/166) of T-CUPs (Figure 3C). DNA features 390 391 supported a diagnosis in 31% (51/166) of T-CUP cases, GEP TOO classification in 13% 392 (21/166), and viral detection in 4% (6/166). Combined GEP classification and mutation 393 profiling features were informative in 10% 16/166 cases (Figure 3D). Types of genomic 394 feature supporting a diagnosis included driver gene mutations (n=36), mutational 395 signatures (n=23), HPV16 (n=5) and EBV (n=1) viral nucleic acids, gene amplification 396 (n=4), gene-fusions (n=3) and high-medium confidence GEP prediction (n=21) (Figure

397 3B). DNA features could narrow the differential diagnosis in a further 11/166 T-CUPs 398 (7%), although a TOO assignment of a single site could not be confidently made (Figure 399 3C). Considering the genomics data, the most frequently suspected cancer types 400 among T-CUPs were lung (n=18, including a single pleomorphic carcinoma of the lung 401 (LUPC)), biliary tract (n=8), breast (n=5), colorectal (n=5), HPV+ SCC (n=5) and kidney 402 (n=4) (Figure 3E).

Lung-CUP was the single largest single group among T-CUPs. Dominant mutational 403 404 Signature 4 (tobacco) was found in 14 cases. Driver gene mutations associated with 405 non-small cell lung cancer (NSCLC) included KEAP1 (Lung OR=9.8), STK11 (Lung OR=14.1), SMARCA4 (Lung OR=2.8), and KRAS (Lung OR=2.1) (Figure 3E, 406 407 Supplementary Figure 1 and Supplementary Table 10). Notably, all but one putative Lung-CUP lacked TTF1 IHC staining. Among the Lung-CUPs where GEP was possible, 408 a high-medium confidence classification of Lung was made in 5/16 cases. Two 409 410 additional T-CUPs that were unresolved had high-medium lung classification, but 411 mutation profiling was unsuccessful, and there was no other evidence to support a lung 412 diagnosis. Three Lung-CUPs were CDX2-positive by IHC but had mutational features 413 consistent with lung cancer, including a Signature 4 (tobacco) in all three cases. GEP 414 was uninformative in these cases as one was classified as colorectal (0.9-confidence 415 probability), and two were predicted SCC, a non-specific classification but potentially in 416 keeping with lung-squamous cancer (Figure 3E, Supplementary Table 2). These CDX2+ Lung-CUPs were favored to be enteric-like lung adenocarcinomas <sup>37</sup>. 417

418

419 Eight ADNOS tumors were putatively diagnosed as intrahepatic cholangiocarcinomas 420 mutations in BAP1 (cholangiocarcinoma OR=7.2) supported by and IDH1 421 (cholangiocarcinoma OR=32) (Figure 3E and Supplementary Table 10). Seven of these 422 tumors presented with liver masses. These tumors lacked KRAS mutations, making a pancreatic origin less likely, given that KRAS mutations occur in approximately 90% of 423 pancreatic adenocarcinomas (Supplementary Table 9-10) <sup>38</sup>. Hotspot IDH1 (R132C) 424 425 mutations have the highest frequency in cholangiocarcinoma (cholangiocarcinoma 426 OR=33) but can be detected at a low frequency in melanoma (2%, melanoma OR=3.6). Similarly, FGFR2-fusions are frequently detected in intrahepatic cholangiocarcinoma 427 (cholangiocarcinoma OR>100)<sup>39-41</sup>, a feature that supported a cholangiocarcinoma 428 429 diagnosis in two T-CUP cases (Supplementary Table 2 and 10).

430

In four T-CUPs subsequently assigned a kidney TOO, two cases expressed PAX8 by 431 IHC, both confirmed by high PAX8 mRNA expression (z-score > 2), and an additional 432 433 case did not have PAX8 IHC performed but had high PAX8 mRNA expression. The 434 fourth case did not have PAX8 staining or high PAX8 mRNA expression. Only two cases were classified as kidney cancer by GEP (Figure 3E). Driver mutations 435 436 significantly associated with kidney cancer, and detected among kidney-CUPs, included 437 BAP1 (kidney OR=7.6) and NF2 (kidney OR=7.2). Another case had a truncating FH 438 mutation consistent with FH-deficient kidney cancer (kidney OR=8.1) (Supplementary 439 Figures 1). Notably, no VHL mutations were detected, representing the most common driver gene in renal cell carcinoma (RCC) (42.5% RCC in GENIE, OR=763). Another 440

assigned kidney case was confirmed as a recurrence of late-onset adult Wilm's tumor
by detecting a somatic *FGFR1* (p.K656D) mutation in both the original primary tumor
and a recurrent tumor that presented over twenty years after first diagnosis
(Supplementary Table 2 and 10).

445

#### 446 Unresolved CUPs have a reduced survival outcome compared to resolved CUPs

Of the 215 patients, 177 patients had recorded survival data. Among all cases recruited 447 448 to the SUPER study, the majority were classified as unfavorable according to the ESMO guidelines (137/159= 86% of T-CUP, and 39/48=81% of LP/HR-CUP, where data was 449 available) <sup>5</sup> (Figure 4A). Overall, 85% of the cohort was unfavorable CUP and, as 450 451 expected, these had significantly poorer overall survival (OS)- by log-rank test (p < r452 0.001), with a median OS of 11 months compared to a median OS of 15 months for favorable CUP. Additionally, 46% of unfavorable CUP achieved 12 months of survival 453 454 compared with 92% of favorable CUP (Figure 4B). Furthermore, log-rank testing showed longer survival in LP/HR-CUPs, and T-CUPs assigned a single TOO after 455 456 interpretation of the genomics data, compared with diagnostically unresolved T-CUPs 457 (p=0.04, Figure 4C). Multivariate Cox-regression analysis, including gender, age, ECOG performance, and ESMO prognosis groups (Figure 4D), showed that T-CUPs had 458 worse survival outcomes compared to LP/HR-CUPs (HR=1.89, 95% CI 1.13-3.2, 459 460 p=0.016) while there was no significant difference between LP/HR-CUPs and resolved T-CUPs (HR=1.18, 95% CI 0.65-2.1, p=0.595). 461

462

## 463 **Discussion**

The reported incidence of CUP has decreased in recent years <sup>1</sup>. This is most likely due 464 to increased awareness and standardization of investigations, including access to more 465 466 specific IHC stains, improved diagnostic imaging, and the use of molecular profiling<sup>1</sup>. Consistent with other large retrospective CUP studies, we found that approximately 467 one-quarter of CUP may be assigned a likely TOO based on a centralized 468 histopathology review <sup>42,43</sup>. This is similar to the recent experience of the international 469 470 CUP clinical trial CUPISCO, where ~20% of patients had a single primary site diagnosis supported by available evidence or was TOO was strongly suspected <sup>44</sup>. In the current 471 472 study, we have shown that incorporating DNA and RNA tests may help to resolve more 473 than a third of T-CUP cases not otherwise resolved using conventional testing. 474 Importantly, despite GEP being the most commonly explored molecular test for 475 resolving CUP, we found DNA sequencing was of potentially greater diagnostic value among CUP tumors due to many CUPS having an atypical transcriptional profile. 476

477

Despite positive evidence that GEP can be diagnostically informative for CUP, cases with poorly differentiated histopathology and atypical disease presentation remain challenging <sup>45,46</sup>. This is perhaps not surprising given that GEP classification relies upon the expression of cellular differentiation markers that are often lost or equivocal in CUP tumors <sup>47</sup>. Our observation that fewer CUP pass a high-medium confidence GEP classification compared to known metastatic cancers, hence have a reduced classifier performance, is supported by other studies. For instance, the CancerTYPE ID

485 (Biotheranostics) 92-gene test, which had extensive multisite validation, showed an 486 overall accuracy of 85% for known cancer metastases. But in CUP, the concordance of GEP with IHC and clinicopathological evidence was lower at 75% for LP-CUP and 70% 487 compared to the clinical picture only <sup>7</sup>. Additionally, rare malignancies are infrequently 488 included in the training set of TOO classifiers <sup>6</sup>, which poses a limitation for rare entities 489 490 among a cohort of CUP. More specifically, subsets of lung and biliary cancers can be 491 problematic for GEP classifiers to resolve. For example, among lung CUPs, GEP 492 classification was found to be concordant with a latent primary tumor in only 50% of cases <sup>13</sup>. GEP classification accuracy can also be low for cholangiocarcinomas, as the 493 transcriptional profile is similar to pancreatic and upper gastrointestinal neoplasms <sup>10</sup>. 494 495 Notably, some previously described GEP and DNA methylation tests have also 496 excluded cholangiocarcinoma in their models or combined them into а pancreaticobiliary class <sup>9,48</sup>. We found that DNA sequencing may be particularly useful 497 498 pancreaticobiliary CUPs given that characteristic in gene mutations of 499 cholangiocarcinomas can have both diagnostic and occasionally therapeutic significance, including alterations in IDH1, FGFR2, and BAP1 <sup>39-41</sup>. 500

501

Integrated molecular profiling of CUP can help identify rare disease subtypes and our data supports their being some recurrent CUP entities. We identified examples of pulmonary enteric adenocarcinomas that lack TTF1 expression but can express the gastrointestinal marker CDX2 <sup>37</sup>. GEP or IHC alone could not resolve such cases, given their atypical profile; however, they still retained DNA features highly suggestive of

507 NSCLC, including a tobacco mutational signature and somatic mutations in KRAS. 508 STK11, and SMARCA4. SMARCA4-deficient lung cancers are known to lack TTF1 expression <sup>49</sup> and are likely to be frequent in the CUP population <sup>19,20</sup>. SMARCA4-509 510 deficient lung cancer models similarly lose expression of lung differentiation markers 511 and have a pro-metastatic behavior consistent with aggressive clinical course and poor survival outcomes in patients <sup>50</sup>. Kidney cancers are another emerging CUP entity 512 representing ~4-6% of CUPs <sup>44,51,52</sup>. Four CUPs in the SUPER cohort were consistent 513 514 with a primary kidney tumor. Interestingly, we found somatic mutations in NF2, FH, and BAP1 in some RCC cases. Somatic NF2 mutations are characteristic of advanced 515 516 papillary renal cell tumors and those with biphasic hyalinizing psammomatous features <sup>53</sup>. Papillary carcinomas have also been found to be enriched among other Kidney-517 CUPs <sup>51,52</sup> with a mutation profile similar to the Kidney-CUPs described in the SUPER 518 cohort <sup>54</sup>. Identifying CUP entities and recurrent therapeutic targets in these groups may 519 help guide future CUP clinical trials. For instance, while empirical chemotherapy is 520 ineffective in RCC, targeted therapies and ICIs are likely more efficacious <sup>51,55</sup>. 521 522 Furthermore, detection of NF2 mutations among RCC and mesothelioma could direct targeted treatment of the Hippo pathway using inhibitors of TEAD auto-palmitoylation <sup>56</sup>, 523 524 which have now entered clinical trials (NCT04665206).

525

526 CUP can be classified into favorable and unfavorable prognosis groups. Given that 527 ~85% of CUPs belong to the unfavorable group, research and clinical trials directed at 528 identifying other treatments for these patients or therapeutic responsive subsets should

529 be sought. Approximately 40% of T-CUPs in the SUPER cohort had potentially 530 actionable mutations and genomic alterations, broadly consistent with other CUP profiling studies <sup>19,20,22</sup>. As curated findings from genomic tests were returned to 531 532 clinicians during the study, it is possible that the genomic data allowed site-specific 533 treatments and access to targeted treatments, potentially explaining the improved survival outcome among the resolved compared to the unresolved T-CUP group. 534 535 Alternatively, genomically resolved CUPs may be enriched for cancer types where 536 targeted or immunotherapy treatments are available and effective.

537

538 In conclusion, we have shown that DNA and RNA tests can be incorporated into a 539 pathology assessment to improve cancer type diagnosis, identify CUP subtypes, and 540 direct treatments. Rather than replacing traditional histopathological analysis, molecular 541 testing can augment conventional testing to either confirm a suspicion of primary tissue 542 of origin or provide robust diagnostic leads that are not otherwise evident using other 543 modalities. In practice, in cases where tissue is limited, it may be more informative to 544 prioritize genomic testing to guide additional investigations before consuming tissue on 545 extended IHC panels. With steady improvements in technology and reduction in the 546 sequencing costs, more comprehensive whole-genome and transcriptome analysis will 547 likely increase the sensitivity to detect features such as structural variants and mutational signatures that are not reliably detected by panel sequencing <sup>57</sup>. Recent 548 549 studies have also utilized machine-learning for classification based on genome-wide 550 patterns of somatic mutations that are not otherwise interpretable by human curation

<sup>58,59</sup> and combined DNA and RNA features <sup>60</sup> to improve the TOO prediction accuracy further (60-91% and 94%, respectively). Although molecular testing is not currently recommended in most CUP guidelines, careful prospective evaluation of these tests may justify their cost, helping to resolve cancer type in a significant fraction of CUP cases as well as direct treatments that will ultimately translate to better outcomes for patients.

- 557
- 558

#### 559 Figure legends

560 Figure 1: Gene expression profiling (GEP) tissue of origin classification of known metastatic cancers and SUPER cancer of unknown primary (CUP) tumors. A) 561 NanoString GEP classifier was tested on 188 known origin metastatic tumors with 562 563 confusion matrix showing concordance of tissue of origin prediction and known cancer 564 type. B) GEP classifier tested on latent primary/histology resolved (LP/HR)-CUPs showing concordance between the likely tissue of origin and the predicted cancer type. 565 LP/HR-CUPs representing cancer types that were not represented in the classifier 566 model were removed from analysis C) Fraction of cases within confidence probability 567 568 score grouping contrasting classification of true-CUPs (T-CUP) and LP/HR-CUPs 569 combined with known metastatic tumors (unclassified <0.5, low  $\geq$  0.5 and  $\leq$  0.7 medium 570 confidence  $\geq$  0.8 and  $\leq$  0.9, high confidence = 1). D) GEP cancer class predictions of all 571 T-CUPs with high-medium confidence predictions.

573 Figure 2: DNA mutational profiling of the SUPER cancer of unknown primary (CUP) 574 cohort. Oncoplot shows somatic mutations in CUPs in descending order of frequency. 575 Genes and mutational features colored in red are actionable and targeted in the 576 CUPISCO trial. The proportion of mutations in the SUPER CUPs was compared with the AACR GENIE CUP cohort (right-hand bar plot). The left-hand plot of the variant 577 578 allele frequency (VAF) distribution per gene. The top bar plot shows the number of 579 coding mutations per sample. Annotations include OncoTree class for true-CUPs (T-580 CUP) or the assigned tumor class for latent primary/histology resolved (LP/HR)-CUPs, detection of COSMIC mutational signatures (V2): smoking signature, ultra-violet (UV) 581 signature, DNA mismatch repair signature, oncoviruses: Human papillomavirus 16 582 583 (HPV16) and Epstein-Barr virus (EBV), and tumor mutation burden (TMB) status: High 584 >10 mutations/Mb or Low <10 mutations/Mb.

585

Figure 3: Identification of diagnostically useful DNA features using AACR Project 586 587 GENIE mutation data and summary of evidence used to support tissue of origin (TOO) diagnosis among SUPER cancer of unknown primary (CUP) cases. A) Volcano plot 588 showing significantly mutated features by cancer types using GENIE pan-caner cohort. 589 590 All genes are plotted for all cancers using a Fisher's exact test to calculate adjusted p-591 values and odds ratio (OR) (significance threshold adjusted p-value < 0.05 and OR >1). 592 B) Proportion and number of cases where each genomic feature supported a putative 593 TOO for true-CUPs (T-CUP) and latent primary/histology resolved (LP/HR)-CUPs. Genomic features included single nucleotide variants (SNV), Gene expression profiling 594

(GEP), mutational signatures, oncoviral sequences, and copy number amplifications (CNA). C) OncoTree cancer classification of T-CUPs before and after genomic analysis. CUPs were either resolved to a putative TOO, had reduced occult diagnosis, or remained T-CUP. D) Proportion of cases where DNA and/or GEP classification supported TOO diagnosis among T-CUPs. E) Detailed summary of supportive genomic features and IHC staining used to assign a putative TOO for all genomically resolved T-CUPs. NGS= Next generation sequencing.

602

Figure 4: A comparison of overall survival outcome among SUPER CUP patients based 603 604 on clinical and diagnostic groups A) Proportion and number of true-CUPs (T-CUP) and 605 latent primary/histology resolved (LP/HR)-CUPs classified by European Society of 606 Medical Oncology (ESMO) favorable and unfavorable prognosis groups. B) Kaplan-607 Meier curve of overall survival (OS) in unfavorable and favorable CUP types. Censored at 12 months and significance using log-rank p-values. C-D) Log-rank test and 608 609 multivariable Cox-proportional hazard model of SUPER CUP clinical and diagnostic 610 group. Data censored at 12 months and significance using log-rank p values for Kaplan-611 Meier analysis. Cox-proportional hazard model including covariates of ECOG, age (>60 612 or <60), ESMO favorable and unfavorable outcome categories, and patient sex. GR = 613 genomically resolved T-CUPs, U= unfavorable type, F= favorable type, HR= hazard 614 ratio, CI= confidence interval.

615

## 617

## Table 1. Study cohort characteristics

| Characteristics           | Count      | Proportion |
|---------------------------|------------|------------|
| Total cohort              | 215        | 100%       |
| Age mean (range)          | 61 (20-86) |            |
| Sex                       |            |            |
| Male                      | 89         | 41%        |
| Female                    | 107        | 49%        |
| Unrecorded                | 19         | 9%         |
| ECOG                      |            |            |
| 0                         | 67         | 31%        |
| 1                         | 101        | 47%        |
| 2                         | 24         | 11%        |
| 3                         | 1          | 0.5%       |
| Not determined            | 22         | 10%        |
| Previous cancer diagnosis | 58         | 27%        |
| ESMO Outcome              |            |            |
| Favourable                | 31         | 14%        |
| Unfavourable              | 176        | 82%        |
| Not determined            | 8          | 4%         |
| Gene Expression Profile   | 191        | 89%        |
| NanoString                | 172        | 80%        |
| CUPguide                  | 19         | 9%         |
| DNA sequencing            | 201        | 93%        |
| Both molecular tests*     | 177        | 82%        |

\*DNA sequencing and GEP performed successfully

### 619 Reference list

Rassy, E. & Pavlidis, N. The currently declining incidence of cancer of unknown primary. *Cancer Epidemiol* 61, 139-141 (2019).

Australian Institute of Health and Welfare (AIHW) 2018 Cancer Data in Australia;
Australian Cancer Incidence and Mortality (ACIM) books: cancer of unknown primary
site Canberra: AIHW.

- Massard, C., Loriot, Y. & Fizazi, K. Carcinomas of an unknown primary origin--diagnosis
  and treatment. *Nat Rev Clin Oncol* 8, 701-710 (2011).
- Hyphantis, T., Papadimitriou, I., Petrakis, D., Fountzilas, G., Repana, D.,
  Assimakopoulos, K. et al. Psychiatric manifestations, personality traits and health-related
  quality of life in cancer of unknown primary site. *Psycho-oncology* 22, 2009-2015 (2013).
- Fizazi, K., Greco, F. A., Pavlidis, N., Daugaard, G., Oien, K., Pentheroudakis, G. et al.
  Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis,
  treatment and follow-up. *Ann Oncol* 26, v133-138 (2015).
- 633 6 Erlander, M. G., Ma, X. J., Kesty, N. C., Bao, L., Salunga, R. & Schnabel, C. A.
  634 Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor
  635 classification. *J Mol Diagn* 13, 493-503 (2011).
- Kerr, S. E., Schnabel, C. A., Sullivan, P. S., Zhang, Y., Singh, V., Carey, B. et al.
  Multisite validation study to determine performance characteristics of a 92-gene
  molecular cancer classifier. *Clin Cancer Res* 18, 3952–3960 (2012).

- Hainsworth, J. D. & Greco, F. A. Gene expression profiling in patients with carcinoma of
  unknown primary site: from translational research to standard of care. *Virchows Arch*464, 393-402 (2014).
- Moran, S., Martínez-Cardús, A., Sayols, S., Musulén, E., Balañá, C., Estival-Gonzalez,
  A. et al. Epigenetic profiling to classify cancer of unknown primary: a multicentre,
  retrospective analysis. *Lancet Oncol* **17**, 1386-1395 (2016).
- Zhao Y, P. Z., Namburi S, Pattison A, Posner A, Balachander S, Paisie C.A., Reddi H.V.,
  Rueter J, Gill AJ, Fox S, Raghav KPS., Flynn WF, Tothill RW, Li S, Karuturi RKM,
  George J. CUP-AI-Dx: a tool for inferring cancer tissue of origin and molecular subtype
  using RNA gene-expression data and artificial intelligence. *EBioMedicine* (2020).
- Handorf, C. R., Kulkarni, A., Grenert, J. P., Weiss, L. M., Rogers, W. M., Kim, O. S. et al.
  A multicenter study directly comparing the diagnostic accuracy of gene expression
  profiling and immunohistochemistry for primary site identification in metastatic tumors. *Am J Surg Pathol* 37, 1067-1075 (2013).
- Tothill, R. W., Shi, F., Paiman, L., Bedo, J., Kowalczyk, A., Mileshkin, L. et al.
  Development and validation of a gene expression tumour classifier for cancer of
  unknown primary. *Pathology* 47, 7-12 (2015).
- Greco, F. A., Lennington, W. J., Spigel, D. R. & Hainsworth, J. D. Molecular profiling
  diagnosis in unknown primary cancer: accuracy and ability to complement standard
  pathology. *J Natl Cancer Inst* **105**, 782-790 (2013).

Hainsworth, J. D., Rubin, M. S., Spigel, D. R., Boccia, R. V., Raby, S., Quinn, R. et al.
Molecular gene expression profiling to predict the tissue of origin and direct site-specific
therapy in patients with carcinoma of unknown primary site: a prospective trial of the
Sarah Cannon research institute. *J Clin Oncol* **31**, 217-223 (2013).

Yoon, H. H., Foster, N. R., Meyers, J. P., Steen, P. D., Visscher, D. W., Pillai, R. et al.
Gene expression profiling identifies responsive patients with cancer of unknown primary
treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). *Ann Oncol* 27, 339-344 (2016).

Haratani, K., Hayashi, H., Takahama, T., Nakamura, Y., Tomida, S., Yoshida, T. et al.
Clinical and immune profiling for cancer of unknown primary site. *J Immunother Cancer* **7**, 251 (2019).

- Fizazi, K., Maillard, A., Penel, N., Baciarello, G., Allouache, D., Daugaard, G. et al.
  LBA15\_PRA phase III trial of empiric chemotherapy with cisplatin and gemcitabine or
  systemic treatment tailored by molecular gene expression analysis in patients with
  carcinomas of an unknown primary (CUP) site (GEFCAPI 04). *Annals of Oncology* 30
  (2019).
- Tothill, R. W., Li, J., Mileshkin, L., Doig, K., Siganakis, T., Cowin, P. et al. Massivelyparallel sequencing assists the diagnosis and guided treatment of cancers of unknown
  primary. *J Pathol* 231, 413-423 (2013).
- Ross, J. S., Wang, K., Gay, L., Otto, G. A., White, E., Iwanik, K. et al. Comprehensive
  Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted
  Therapies. *JAMA Oncol* 1, 40-49 (2015).

- Varghese, A. M., Arora, A., Capanu, M., Camacho, N., Won, H. H., Zehir, A. et al.
  Clinical and molecular characterization of patients with cancer of unknown primary in the
  modern era. *Ann Oncol* 28, 3015-3021 (2017).
- Löffler, H., Pfarr, N., Kriegsmann, M., Endris, V., Hielscher, T., Lohneis, P. et al.
  Molecular driver alterations and their clinical relevance in cancer of unknown primary
  site. *Oncotarget* 7, 44322-44329 (2016).
- Ross, J. S., Sokol, E. S., Moch, H., Mileshkin, L., Baciarello, G., Losa, F. et al.
  Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin:
  Retrospective Molecular Classification Considering the CUPISCO Study Design. *Oncologist* (2020).
- 691 23 Consortium, A. P. G. AACR Project GENIE: Powering Precision Medicine through an
  692 International Consortium. *Cancer Discov* 7, 818-831 (2017).
- Chakravarty, D., Gao, J., Phillips, S., Kundra, R., Zhang, H., Wang, J. et al. OncoKB: A
  Precision Oncology Knowledge Base. *JCO Prec Oncol* 1-16 (2017).
- Forbes, S. A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J. et al.
  COSMIC: somatic cancer genetics at high-resolution. *Nucleic Acids Res* 45, D777–D783
  (2017).
- Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A. et al. The
  cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer
  Genomics Data. *Cancer Discov* 2, 401 (2012).

- 701 27 Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O. et al.
  702 Integrative analysis of complex cancer genomics and clinical profiles using the
  703 cBioPortal. *Sci Signal* 6, pl1 (2013).
- Groschel, S., Bommer, M., Hutter, B., Budczies, J., Bonekamp, D., Heining, C. et al.
  Integration of genomics and histology revises diagnosis and enables effective therapy of
  refractory cancer of unknown primary with PDL1 amplification. *Cold Spring Harb Mol Case Stud* 2, a001180 (2016).
- Kundra, R., Zhang, H., Sheridan, R., Sirintrapun, S. J., Wang, A., Ochoa, A. et al.
  OncoTree: A Cancer Classification System for Precision Oncology. *JCO Clin Cancer Inform* 5, 221-230 (2021).
- McEvoy, C. R., Semple, T., Yellapu, B., Choong, D. Y., Xu, H., Mir Arnau, G. et al.
  Improved next-generation sequencing pre-capture library yields and sequencing
  parameters using on-bead PCR. *Biotechniques* 68, 48–51 (2020).
- Chang, M. T., Bhattarai, T. S., Schram, A. M., Bielski, C. M., Donoghue, M. T. A.,
  Jonsson, P. et al. Accelerating Discovery of Functional Mutant Alleles in Cancer. *Cancer Discov* 8, 174-183 (2017).
- Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A., Behjati, S., Biankin, A.
  V. et al. Signatures of mutational processes in human cancer. *Nature* 500, 415-421
  (2013).
- 720 33 Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A. et al.
  721 Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets

| 722 | (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical |
|-----|---|
| 723 | Assay for Solid Tumor Molecular Oncology. J Mol Diagn 17, 251-264 (2015).       |

- Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R. et
- al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.
- 726 *J Pathol* **221**, 49–56 (2010).
- 727 35 Cancer Genome Atlas, N. Genomic Classification of Cutaneous Melanoma. *Cell* 161,
  728 1681-1696 (2015).
- 729 36 Cancer Genome Atlas, N. Comprehensive molecular characterization of human colon
  730 and rectal cancer. *Nature* 487, 330-337 (2012).
- 731 37 Li, H. & Cao, W. Pulmonary enteric adenocarcinoma: a literature review. *J Thorac Dis*732 **12**, 3217-3226 (2020).
- 733 38 Network, C. G. A. R. Integrated Genomic Characterization of Pancreatic Ductal
  734 Adenocarcinoma. *Cancer cell* 32, 185–203.e113 (2017).
- Arai, Y., Totoki, Y., Hosoda, F., Shirota, T., Hama, N., Nakamura, H. et al. Fibroblast
  growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of
  cholangiocarcinoma. *Hepatology* 59(4), 1427–1434 (2014).
- Javle, M. M., Murugesan, K., Shroff, R. T., Borad, M. J., Abdel-Wahab, R., Schrock, A.
  B. et al. Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations
  (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH). J *Clin Oncol* 37, 4087-4087 (2019).

Silverman, I. M., Murugesan, K., Lihou, C. F., Féliz, L., Frampton, G. M., Newton, R. C.
et al. Comprehensive genomic profiling in FIGHT-202 reveals the landscape of
actionable alterations in advanced cholangiocarcinoma. *J Clin Oncol* 37, 4080-4080
(2019).

- Greco, F. A., Oien, K., Erlander, M., Osborne, R., Varadhachary, G., Bridgewater, J. et
  al. Cancer of unknown primary: progress in the search for improved and rapid diagnosis
  leading toward superior patient outcomes. *Ann Oncol* 23, 298-304 (2012).
- Horlings, H. M., van Laar, R. K., Kerst, J. M., Helgason, H. H., Wesseling, J., van der
  Hoeven, J. J. et al. Gene expression profiling to identify the histogenetic origin of
  metastatic adenocarcinomas of unknown primary. *J Clin Oncol* 26(27), 4435–4441
  (2008).
- Pauli, C., Bochtler, T., Mileshkin, L., Baciarello, G., Losa, F., Ross, J. S. et al. A
  Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP)
  According to ESMO Guidelines: The CUPISCO Trial Experience. *Oncologist* 26, e769e779 (2021).
- Ramaswamy, S., Tamayo, P., Rifkin, R., Mukherjee, S., Yeang, C. H., Angelo, M. et al.
  Multiclass cancer diagnosis using tumor gene expression signatures. *Proc Natl Acad Sci U S A* 98, 15149-15154 (2001).
- Palmeri, S., Lorusso, V., Palmeri, L., Vaglica, M., Porta, C., Nortilli, R. et al. Cisplatin and
  gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of
  unknown primary site : results of an Italian multicenter, randomized, phase II study. *Cancer* 107, 2898-2905 (2006).

- Pavlidis, N. Optimal therapeutic management of patients with distinct clinicopathological
  cancer of unknown primary subsets. *Ann Oncol* 23 Suppl 10, x282-285 (2012).
- Monzon, F. A., Lyons-Weiler, M., Buturovic, L. J., Rigl, C. T., Henner, W. D., Sciulli, C. et
  al. Multicenter validation of a 1,550-gene expression profile for identification of tumor
  tissue of origin. *J Clin Oncol* 27, 2503-2508 (2009).
- 769 49 Herpel, E., Rieker, R. J., Dienemann, H., Muley, T., Meister, M., Hartmann, A. et al. 770 SMARCA4 and SMARCA2 deficiencv in non-small cell luna cancer: 771 immunohistochemical survey of 316 consecutive specimens. Ann Diagn Pathol 26, 47-51 (2017). 772
- Concepcion, C. P., Ma, S., LaFave, L. M., Bhutkar, A., Liu, M., DeAngelo, L. P. et al.
  Smarca4 Inactivation Promotes Lineage-Specific Transformation and Early Metastatic
  Features in the Lung. *Cancer Discov* 12, 562-585 (2022).
- Greco, F. A. & Hainsworth, J. D. Renal Cell Carcinoma Presenting as Carcinoma of
  Unknown Primary Site: Recognition of a Treatable Patient Subset. *Clin Genitourin Cancer* 16, e893-e898 (2018).
- Overby, A., Duval, L., Ladekarl, M., Laursen, B. E. & Donskov, F. Carcinoma of
  Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic
  and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive
  Patients Treated With Targeted Therapy and Review of Literature. *Clin Genitourin Cancer* 17, e32-e37 (2019).

- Yakirevich, E., Perrino, C., Necchi, A., Grivas, P., Bratslavsky, G., Shapiro, O. et al. NF2
  mutation-driven renal cell carcinomas (RCC): A comprehensive genomic profiling (CGP)
  study. *J Clin Oncol* **38**, 726-726 (2020).
- Wei, E. Y., Chen, Y. B. & Hsieh, J. J. Genomic characterisation of two cancers of
  unknown primary cases supports a kidney cancer origin. *BMJ Case Rep* **2015** (2015).
- 55 Escudier, B. Combination Therapy as First-Line Treatment in Metastatic Renal-Cell
  Carcinoma. N Eng J Med 380, 1176-1178 (2019).
- Tang, T. T., Konradi, A. W., Feng, Y., Peng, X., Ma, M., Li, J. et al. Small Molecule
  Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth
  of NF2-deficient Mesothelioma. *Mol Cancer Ther* 20, 986–998 (2021).
- Priestley, P., Baber, J., Lolkema, M. P., Steeghs, N., de Bruijn, E., Shale, C. et al. Pancancer whole-genome analyses of metastatic solid tumours. *Nature* 575, 210-216
  (2019).
- Yuan, Y., Shi, Y., Li, C., Kim, J., Cai, W., Han, Z. et al. DeepGene: an advanced cancer
  type classifier based on deep learning and somatic point mutations. *BMC Bioinformatics* **17**, 476 (2016).
- Jiao, W., Atwal, G., Polak, P., Karlic, R., Cuppen, E., Subtypes, P. T. et al. A deep
  learning system accurately classifies primary and metastatic cancers using passenger
  mutation patterns. *Nat Commun* **11**, 728 (2020).

| 803 | 60 | Abraham, J.  | . Heimberger.    | A. B.   | . Marshall. | J H | leath. E         | Drabick. | J., Helmstetter,   | A. et al.   |
|-----|----|--|------------------|---------|-------------|-----|------------------|----------|--------------------|-------------|
| 000 | 00 | <i>i</i> with a main in the second | , 1101111001901, | / \. D. | , maiorian, | 0., | ющи, <b>с</b> ., | Drabion, | 0., 11011101010101 | 7 ti Ot ali |

- 804 Machine learning analysis using 77,044 genomic and transcriptomic profiles to
- accurately predict tumor type. *Transl Oncol* **14**, 101016 (2021).

806

807 Supplementary Information

## 808 Supplementary Methods

- 809 **Supplementary Figure 1**: Diagnostically useful mutated features per cancer type using
- 810 GENIE pan-caner cohort.
- 811 Supplementary Figure 2: Supportive genomic features and IHC staining for latent
- 812 primary and histology resolved CUPs.

813

814 Supplementary Tables 1-12

#### 816 Acknowledgments

We acknowledge Cameron Patrick of the Melbourne Statistical Consulting Platform for 817 818 providing statistical support. We wish to thank Jillian Hung and Niklyn Nevins, SUPER 819 study coordinators at Westmead and Blacktown, Lisa Kay at Nepean, Karin Lyon (ethics 820 and governance), and acknowledge the contributions of the Nepean Cancer Biobank 821 and the Westmead GynBiobank for facilitating the study. The authors would like to 822 acknowledge the American Association for Cancer Research and its financial and 823 material support in the development of the AACR Project GENIE registry, as well as 824 members of the consortium for their commitment to data sharing. Interpretations are the 825 responsibility of study authors. We wish to acknowledge the patients who have 826 contributed to this study and the CUP consumer steering committee, Cindy Bryant 827 (chair), Kym Sheehan, Christine Bradford, Clare Brophy, Dale Witton, and Frank Stoss.

## 828 Ethics Approval / Consent to Participate

All participating patients provided informed consent to partake in the study. This was approved by the Peter MacCallum Cancer Centre (PMCC) human research ethics committee (HREC protocol: 13/62).

#### 832 Author Contribution Statement

RT and LM conceived the study. AP performed the analysis, drafted the figures and
tables. OWJP undertook the histopathology review and data analysis. TS and LM
reviewed the clinical data. CW, KF, SW collected the data for the study. ADF, NW, CSK,

BG, CS, MS, IMC, GR, MW, NK screened patients for eligibility. DE and NT developed
the NanoString classifier, and JG and SB validated the classifier. GW, SW, AB, AJG,
BJS, DB, SF, RJH contributed samples for training the classifier. AF, HX and SF
performed the mutation profiling. APa performed the bioinformatic analysis. AP and RT
co-wrote the manuscript. All authors critically reviewed the manuscript. PS, DB, LM and
RT are the principal investigators and obtained research funding to support the study.

#### 842 Funding Statement

The study was supported by funding from Cancer Australia (APP1048193, APP1082604) and the Victorian Cancer Agency (TRP13062). RWT was supported by funding from the Victorian Cancer Agency (TP828750). The Westmead, Blacktown and Nepean study sites were supported by the Cancer Institute NSW 11/TRC/1-06, 15/TRC/1-01 and 15/RIG/1-16.

#### 848 Data Availability Statement


The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

851

852

medRxiv preprint doi: https://doi.org/10.1101/2022.06.24.22276729; this version posted June 27, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. а Thyroid unclassified 1 1 1 1 9 Testi SCC SCC 1 Sarcoma Sarcoma Prostate Prostate GEP Classification 1 1 **GEP** Classification 1 Pancreas 7 Pancreas Neuroendocrine Neuroendocrine Ovary Ovary Mesothelioma 1 Melanoma Melanoma 1 Lung 1 Lung 1 4 Liver Live Kidney Kidney Gastric 1 1 Gastric 1 1 Colorectal I**5** 1 1 Colorectal Cholangiocarcinoma 1 Breas Breast 11 Bladder Bladde 4 2 Bladder Lung Breast Cholangiocarcinoma Colorectal Gastric Kidnev Sarcoma Liver Melanoma Mesothelioma Ovan Veuroendocrine Breast Pancrea Cholangic Lung Thyroic Bladde Colorecta Kidne Ovary/Fallopian tube SCC Thymus SCC Tonsi Prostat Gastri Pancrea: Pancreatic NE<sup>-</sup> Prostat Melanom Mesotheliom Sarcom Adren SCC cutaneol SCC esophogast SCC Pe Fraction Fraction prediction predictions 1.00 1.00 LP/HR-CUP Known metastatic cancer 0.75 0.75 0.50 0.50 0.25 0.25 С d 0.6 30% Known tumours Proportion Proportion T-CUP 0.4 20% 0.2 10% 0.0 0% SCC High Med Low unclassified Liver Colorecta Breast Luna Bladder Pancrea: Sarcoma Cholangiocarcinom Gastri Oval Mesothelion Neuroendocri Confidence level

GEP prediction



#### Mutation

- Splice\_Site
- Missense\_Mutation
- Nonsense\_Mutation Frame\_Shift\_Del
- Frame\_Shift\_Ins
- In\_Frame\_Ins
- Del
- Amp
- Multi\_Hit
- Complex\_Event
- Oncotree / Class
- SCC p16+ AD CK7-CK20-
- AD CK7+CK20-
- PDC
- Breast Colorectal
- Lung
- Sarcoma
- Gastric

- Prostate Cholangio
- NECNOS
- Uterus NETNOS
- ADNOS
  - Mesothelioma

- AD CK7+CK20+ Melanoma

Pancreas

Adrenal

Thyroid

Ampulla

SCC Penile

SCC cutaneous

- UDMN
- AD CK7-CK20+CDX2+
- Ovary/Fallopian tube SCCNOS
- HighTMB

Gene proportion

- Genie CUP
- T-CUP
- SCC Thymus SCC esophogastric Kidney

- Mutational feature detected NA
- Yes

#### TMB

- Low TMB

b

